Antitumor efficacy of 34.5ENVE: A transcriptionally retargeted and vstat120-expressing oncolytic virus

Ji Young Yoo, Amy Haseley, Anna Bratasz, E. Antonio Chiocca, Jianying Zhang, Kimerly Powell, Balveen Kaur

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Here, we describe the construction and testing of a novel herpes simplex virus type 1 (HSV-1) derived oncolytic virus (OV): 34.5ENVE (viral ICP34.5 Expressed by Nestin promotor and Vstat120 Expressing), for the treatment of cancer. This virus showed significant glioma-specific killing and antiangiogenic effects in vitro and in vivo. Treatment of subcutaneous and intracranial glioma-bearing mice with 34.5ENVE showed a significant increase in median survival of mice in four different glioma models. Histology and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) revealed reduced microvessel density (MVD) and increased tumoral necrosis in 34.5ENVE-treated tumor tissue compared to control OV-treated tumor tissue. Collectively, these results describe the construction, efficacy, and impact on tumor microenvironment of a transcriptionally driven OV armed with Vstat120 gene expression. These preclinical results will facilitate future clinical testing of 34.5ENVE.

Original languageEnglish (US)
Pages (from-to)287-297
Number of pages11
JournalMolecular Therapy
Issue number2
StatePublished - Feb 2012
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Antitumor efficacy of 34.5ENVE: A transcriptionally retargeted and vstat120-expressing oncolytic virus'. Together they form a unique fingerprint.

Cite this